Since the introduction of biological therapies almost 2 decades ago, specifically, the anti-TNFα agents, major alterations of the natural history of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) have been observed (1, 2). This evidence concerns the gene TNF and inflammatory bowel disease.